Cancer Biomarkers Market By Type (Genetic Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Proteomic Biomarkers), By Type of Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer), By Type of Profiling Technologies (Immunoassays, Omics Technologies, Cytogenetics, Imaging Technologies, Bioinformatics), By Application (Diagnostics, Drug Discovery & Development, Prognostics, Risk Assessment) - Growth, Future Prospects, and Competitive Analysis, 2017-2025

The report titled “Cancer Biomarkers Market- Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” offers strategic insights into the overall cancer biomarkers market along with the market size and estimates for the duration 2015 to 2025. The said research study cover in-depth analysis of multiple market segments based on type, type of cancer, type of profiling technologies, type of application, and different geographies. Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of progression of disease. Factors such as rising prevalence of cancer, increasing support from government and non-government organizations for cancer biomarkers research, aging population, and increasing use of biomarkers in the drug discovery and development process.

For the purpose of this study, the global cancer biomarker market is segmented on the basis of type into genetic biomarkers, epigenetic biomarkers, metabolic biomarkers, proteomic biomarkers, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

On the basis of type of cancer such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The global cancer biomarker market is also segmented on the basis of type of profiling technologies such as immunoassays, omics technologies, cytogenetics, imaging technologies, & bioinformatics. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The global cancer biomarker market is segmented on the basis of type of application such as into diagnostics, drug discovery & development, prognostics, risk assessment, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The geographical segmentation of cancer biomarkers market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2015 to 2025 and their CAGRs for the period 2017 to 2025 are provided in this report.

The cancer biomarkers market is observed as the most diversified and competitive market comprising large number of players.  The market is dominated by several players, depending on their major competencies. The key players in this market are Abbott Laboratories, Affymetrix, Inc., DiagnoCure Inc., Qiagen N.V., Illumina, Inc., Roche Diagnostics Ltd., Quest Diagnostics Inc., Agilent Technologies Inc., Merck & Co. Inc., Hologic, Inc., and Becton Dickinson and Company among others.

Based on the type of cancer, the global cancer biomarkers market is segmented as follows:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Others

Cancer Biomarkers Market

  
In year 2016, breast cancer dominated the cancer biomarkers market by cancer type due to rising prevalence of disease, high awareness associated with early diagnosis, increasing public awareness with assistance of government and non-government organizations, and rising research and development activities in the field of breast cancer diagnosis. During the forecast period 2017 – 2025, lung cancer was observed as the fastest growing segment due to key driving factors such as rising prevalence of lung cancer due to increase in air pollution and frequent smoking observed in young generation.

Based on the type of application, the global cancer biomarkers market is segmented as follows:

  • Diagnostics
  • Drug Discovery & Development
  • Prognostics
  • Risk Assessment
  • Others

Cancer Biomarkers Market
  

Rising prevalence of cancer, increasing demand for efficient diagnosis techniques against cancer, developing research activities in the field of cancer biomarkers, and increasing awareness associated with early cancer diagnosis are the key factors driving the overall cancer biomarkers market. In year 2016, applications segment was dominated by diagnostics due to key driving factors such as increasing public awareness about the importance of early diagnosis of cancer and diagnostic biomarkers enable doctors to decide effective treatment alternatives.

For the purpose of this study, the global cancer biomarkers market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Cancer Biomarkers Market 
 

In base year 2016, North America accounted for the largest share in global cancer biomarkers market due to key driving factors such as high prevalence of cancer, mounting healthcare expenditure leading to rise in demand for efficient diagnostic tests and health care services, and incessant technological advancements in the cancer biomarkers industry. According to the American Cancer Society, in 2017 about 190,500 cancer deaths in the US will be caused by cigarette smoking alone. An estimated 20% of all cancers diagnosed in the US are caused by a combination of excess body weight, physical inactivity, excess alcohol consumption, and poor nutrition, and thus could also be prevented. During forecast period 2017 – 2025, Asia Pacific was observed as the fastest growing region in cancer biomarkers market due to rising prevalence and awareness of cancer, supportive government policies, market expansion by key market players, and rising application of biomarker tests for cancer diagnosis.

Choose License Type
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58676
Report Format:   PDF
Pages:   120
Rating:    4.5 (60)
Connect With Us
+1-408-641-3282
24/7 Research Support